A tablet version of Norvir (ritonavir) has been approved by the U.S. Food and Drug Administration (FDA), according to notices from the agency and Norvir’s manufacturer Abbott Laboratories. The film-coated tablet’s prime advantage over Norvir capsules is its heat-stable formulation that doesn’t require refrigeration —a significant advantage, notably in parts of the world where refrigeration and climate control are not widely available.
“Approximately one-third of all HIV-positive patients in treatment use Norvir in combination with other antiretroviral medicines. The heat-stable tablet formulation may allow these patients greater flexibility to store and carry their medication with them,” said Renslow Sherer, MD, professor of medicine, section of infectious diseases and global health and director, International HIV Training Center, University of Chicago Hospitals. “For patients who may not have access to refrigeration, this new formulation is also important.”